在复发或转移性鼻癌中使用安洛提尼布单疗法:多中心病例系列分析
Guan-Jie Qin1,2, Yi-Xin Su3, Yong Liang4
11Department of Radiation Oncology, Affiliated Hospital of Guilin Medical University, Guilin, China.
Radiology and oncology
|December 16, 2025
概括
安洛提尼布单一治疗对复发性或转移性鼻癌 (rmNPC) 显示出前景. 治疗表明可接受的毒性和积极的疗效,包括73.3%的疾病控制率.
科学领域:
- 在瘤学瘤学.
- 医学研究 医学研究
背景情况:
- 安洛丁尼布在各种固体瘤中表现出治疗潜力.
- 复发性或转移性鼻癌 (rmNPC) 存在重大治疗挑战.
研究的目的:
- 评估安洛提尼布单一治疗在rmNPC患者中的疗效和安全性.
- 确定客观反应率 (ORR),无进展生存率 (PFS) 和整体生存率 (OS).
主要方法:
- 对30名患有rmNPC的患者进行了回顾性研究.
- 安洛丁尼布单一治疗每天服用12毫克或10毫克.
- 主要终点:ORR;次要终点:PFS,OS,以及毒性.
主要成果:
- 目标应答率 (ORR) 为13.3%;疾病控制率为73.3%.
- 平均整体存活时间 (OS) 为11.5个月;平均无进展存活时间 (PFS) 为5.7个月.
- 常见的3级+不良事件包括手脚综合征和口腔粘膜炎 (13.3%).
结论:
- 安洛提尼布单一治疗在rmNPC患者中显示出积极的疗效.
- 治疗耐受性很好,可接受的毒性概况.
更多相关视频
06:08Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
Published on: June 2, 2023
2.2K
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
12.1K
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
lncRNA - Long Non-coding RNAs
9.7K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.7K
